摘要
目的:探讨健脾化瘀解毒方通过抑制细胞焦亡防治胃癌前病变的作用机制。方法:构建胃癌前病变小鼠模型和细胞焦亡模型,将小鼠随机分为空白组,模型组,健脾化瘀解毒方高剂量组(15 g/kg)、低剂量组(7.5 g/kg)和维酶素组(0.2 g/kg),每组10只。分别进行干预后,观察小鼠胃黏膜组织病理变化及焦亡相关分子表达情况。细胞分为空白组、模型组和中药组,空白组与模型组给予空白血清,中药组给予含药血清干预后,除空白组外先后予以LPS、ATP处理。观察焦亡相关分子表达情况。结果:与空白组比较,模型组小鼠胃黏膜NLRP3、GSDMD、HMGB1表达显著升高(P<0.01),健脾化瘀解毒方高、低剂量组可显著降低其表达(P<0.01)。与空白组比较,模型组细胞焦亡关键分子NLRP3、GSDMD、Caspase-1 mRNA和蛋白表达水平升高(P<0.01,P<0.05),I L-1β、I L-18 m R NA表达水平显著升高(P<0.01),中药组可显著降低其表达水平(P<0.01,P<0.05)。结论:健脾化瘀解毒方可通过抑制细胞焦亡防治胃癌前病变。
Objective:To explore the mechanism of Jianpi Huayu Jiedu Formula(JHJF)prohibiting gastric precancerous lesions through inhibiting pyroptosis.Methods:The mouse models and cell models were constructed.The mice were randomly divided into control group,model group,JHJF high-dose(15 g/kg),low-dose(7.5 g/kg)groups and Vitacoenzyme group(0.2 g/kg),10 in each group.The expression of pyroptosis markers were observed after the intervention.Cells were divided into control group,model group and the TCM group.The control group and model group were given blank serum,and after the TCM group given the drug serum,the other groups were conducted with LPS and ATP except the control group.The expression of pyroptosis markers were also observed after the intervention.Results:Compared with the control group,the expression of NLRP3,GSDMD and HMGB1 in gastric mucosal tissue of the model group were significantly increased(P<0.01);the expression were decreased in the JHJF highdose and low-dose groups(P<0.01,P<0.05).Compared with the control group,the expression levels of the key molecules of pyroptosis NLRP3,GSDMD and Caspase-1 mRNA and protein were increased in the model group(P<0.01,P<0.05),the expression levels of IL-1βand IL-18 mRNA were significantly increased(P<0.01),while the TCM group dereased the expression level(P<0.01,P<0.05).Conclusion:JHJF could prohibit the progression of gastric precancerous lesions through inhibiting pyroptosis.
作者
张丹
刘伟
田雯
倪家慧
杨良俊
潘华峰
ZHANG Dan;LIU Wei;TIAN Wen;NI Jia-hui;YANG Liang-jun;PAN Hua-feng(Guangzhou University of Chinese Medicine,Guangzhou 510006,China;Dongguan Institute of Guangzhou University of Chinese Medicine,Dongguan 523808,China;Tongde Hospital of Zhejiang Province,Hangzhou 310012,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2022年第5期2831-2835,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金面上项目(No.81973816)
国家自然科学基金青年基金项目(No.82004300)
广东省自然科学基金面上项目(No.2019A1515010822)
广东省基础与应用基础研究基金项目(No.2019A1515110236)。
